Insider Buying: Evommune (NYSE:EVMN) CFO Acquires 1,000 Shares of Stock

Evommune, Inc. (NYSE:EVMN) CFO Kyle Carver acquired 1,000 shares of the stock in a transaction on Wednesday, July 8th. The stock was bought at an average price of $13.26 per share, with a total value of $13,260.00. Following the transaction, the chief financial officer directly owned 60,335 shares in the company, valued at approximately $800,042.10. This represents a 1.69% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kyle Carver also recently made the following trade(s):

• On Thursday, May 28th, Kyle Carver sold 18,175 shares of Evommune stock. The stock was sold at an average price of $22.84, for a total transaction of $415,117.00.

Evommune Price Performance

Shares of EVMN traded down $0.28 during mid-day trading on Friday, hitting $13.23. 585,866 shares of the company traded hands, compared to its average volume of 1,374,484. Evommune, Inc. has a one year low of $12.07 and a one year high of $33.20. The business has a 50-day moving average of $20.37 and a 200 day moving average of $22.01.

Evommune (NYSE:EVMN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.19. Sell-side analysts anticipate that Evommune, Inc. will post -2.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EVMN has been the subject of a number of recent research reports. Stifel Nicolaus started coverage on Evommune in a research report on Friday, May 1st. They set a “buy” rating and a $54.00 target price for the company. Wall Street Zen cut shares of Evommune from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. William Blair lowered Evommune from an “outperform” rating to a “market perform” rating in a research report on Monday, June 29th. Oppenheimer assumed coverage on shares of Evommune in a report on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 price target for the company. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $48.00 price target on shares of Evommune in a report on Friday, April 10th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.62.

Hedge Funds Weigh In On Evommune

Hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new position in Evommune during the fourth quarter worth $34,000. Strs Ohio acquired a new stake in Evommune in the first quarter valued at $41,000. The Manufacturers Life Insurance Company acquired a new stake in Evommune in the fourth quarter valued at $179,000. XTX Topco Ltd bought a new position in shares of Evommune in the 4th quarter valued at about $321,000. Finally, Oxford Asset Management LLP bought a new position in shares of Evommune in the 4th quarter valued at about $335,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.